- AU$19.15m
- -AU$14.02m
- AU$0.23m
Brief: Opthea Completes Enrollment In First Trial With Sozinibercept
Brief: Opthea To Receive US$35M Commitment And Additional US$50M Funding
Brief: Opthea Announces To Receive US$35M Commitment And Additional US$50M Funding
Australia's Opthea set for best day in a month on clinical trial funding
Brief: Opthea Receives A$8.8 Mln R&D Tax Incentive
Brief: Opthea Appoints Fred Guerard as CEO and Peter Lang as CFO
Brief: Opthea Announces Appointment Of U.S.-Based Executive Frederic Guerard As CEO
Brief: Opthea Seeks Trading Halt
Australia's Opthea hits over 5-yr low after discounted placement
Brief: Opthea Completes Institutional Offer And Increases Capital Raising To A$90.0M
Brief: Opthea Announces A$80M Capital Raise
Brief: Opthea Seeks Trading Halt
Brief: Opthea Announces Departure Of Chief Medical Officer, Appointment Of Senior Medical Advisor
Brief: Opthea Appoints Anshul Thakral As Non-Executive Director Of The Board
Brief: Opthea Receives A$8.7 Million Research And Development Tax Incentive
Brief: Opthea Phase 2B Trial Results Of Opt-302 In Combination With Lucentis® For Wet AMD Published In The Journal Ophthalmology
Jefferies sees promise in Opthea's lead chronic eye disorder drug
Focus: Private equity acquires a taste for drug development
Brief: Opthea Appoints Timothy E. Morris as CFO